Washout Period of Letrozole
Based on FDA labeling, females of reproductive potential should use effective contraception during letrozole treatment and for at least 3 weeks after the last dose 1. This 3-week period represents the official washout recommendation when conception is the concern.
Context-Specific Washout Recommendations
For Conception/Fertility Treatment
- 3 weeks minimum after stopping letrozole before attempting conception 1
- This FDA-mandated washout is based on the drug's teratogenic potential demonstrated in animal studies, where letrozole caused fetal malformations including domed head, vertebral fusion, and incomplete ossification at clinically relevant doses
- The drug label explicitly states that breastfeeding should be avoided during treatment and for at least 3 weeks after the last dose 1
Important caveat: When letrozole is used specifically for ovulation induction in infertility treatment (an off-label use), it is typically given on cycle days 3-7, with conception attempts occurring in that same cycle 2, 3, 4. In this context, the drug is intentionally timed to clear before conception occurs naturally within the treatment cycle.
For Switching Between Aromatase Inhibitors in Breast Cancer Treatment
The provided guidelines do not specify a mandatory washout period when switching from letrozole to another aromatase inhibitor in the adjuvant breast cancer setting 5. The ASCO guidelines reference trials where patients were stratified by "the interval between the last dose of AI and random assignment," but no specific minimum interval is mandated for therapeutic switching.
Clinical consideration: One case report documented that a woman who became amenorrheic during 5 years of tamoxifen resumed menses after just a 2-week course of letrozole 6, demonstrating rapid pharmacodynamic effects. This suggests minimal washout may be needed between endocrine therapies when conception is not a concern.
Pharmacokinetic Basis
While the evidence provided doesn't explicitly state letrozole's elimination half-life, the consistent 3-week recommendation across FDA labeling suggests this timeframe allows for adequate drug clearance (typically 5-7 half-lives for complete elimination). The drug is described as having well-tolerated pharmacokinetics even at doses up to 30 mg in single-dose studies 1.
Safety Data Regarding Fetal Exposure
Despite the FDA warning, recent systematic reviews found no increased risk of congenital malformations with letrozole versus clomiphene in fertility treatment (2.15% malformation rate, 95% CI 1.7-2.5%), which is within the general population baseline of 2-4% 7. However, the FDA warning remains in place based on animal teratogenicity data, making the 3-week washout the medico-legal standard when conception is planned.